News

The acquisition would improve Seattle Genetics' late-stage clinical pipeline with Tucatinib, an orally available and highly selective tyrosine kinase inhibitor (TKI) for patients with HER2-positive metastatic breast cancer As per the terms

CHMP has adopted a positive opinion recommending a label variation for Kyprolis (carfilzomib) to include updated overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial in

In addition, BridgeBio announced that it was launching new subsidiary QED Therapeutics to drive development of infigratinib with an initial financial commitment of $65 million. FGFR has been

The Houston-based company, which develops controllable cellular immunotherapies for cancers and orphan inherited blood disorders, said that the three cases of encephalopathy are thought to be possibly related

TAK-426 is a purified, inactivated, alum-adjuvanted and whole Zika virus vaccine candidate. Zika holds capacity to induce congenital Zika syndrome (CZS), including microcephaly and other congenital brain abnormalities,

The Phase I/II study (STELLAR-001) will evaluate the safety and efficacy of durvalumab, an anti-PD-L1 immune checkpoint inhibitor, in combination with Innate's investigational first-in-class anti-C5aR monoclonal antibody, IPH5401,

The study, led by Dr. Tim Greten at the National Cancer Institute (NCI), is being conducted as part of a Cooperative Research and Development Agreement (CRADA) with the

Sanofi has offered €45 for each of the shares of Ablynx in an all-cash deal. The acquisition will help Sanofi advance the transformation of its research and development

The company has announced the top-line results from the Phase III KRONOS trial, which showed PT010 (budesonide/glycopyrronium/formoterol fumarate 320/14.4/9.6µg, using Aerosphere Delivery Technology, in a pressurised metered-dose inhaler